Zobrazeno 1 - 10
of 32
pro vyhledávání: '"N. Perez-Staub"'
Autor:
Benoist Chibaudel, Annette K. Larsen, Thierry André, Sarah Dumont, Aimery de Gramont, N. Perez-Staub
Publikováno v:
Current Colorectal Cancer Reports. 10:329-338
Adjuvant colon cancer trials compare survival of patients receiving either a standard, approved regimen or a new investigational treatment after curative surgical resection of tumor. The target accrual of trials is on the basis of the statistical pow
Autor:
N. Bahmad, J.F. Tournamille, V. Priou, G. Lebozec, N. Perez-staub, C. bernard Marty, R. Alfonsi, M.A. Mouret-reynier, C. Blein, M.C. Borg, H. Attar-rabia, C. Pers-regouby, A. Jaffre, J. Forget, Z. El Islami
Publikováno v:
European Journal of Cancer. 92:S106-S107
Autor:
V. Priou, R. Alfonsi, G. Lebozec, C. bernard Marty, C. Blein, H. Attar Rabia, J.F. Tournamille, M.A. Mouret-reynier, M.C. Borg, A. Jaffre, N. Bahmad, N. Perez staub
Publikováno v:
Value in Health. 21:S30
Autor:
Pierre-Luc Etienne, Elisabeth Carola, Thierry André, Aimery de Gramont, Andrés Cervantes, Arie Figer, N. Perez-Staub, Isabelle Tabah-Fisch, Laurent Mineur, Fernando Rivera, Marc Buyse, Tomasz Burzykowski, Christophe Louvet, E. Quinaux, Christophe Tournigand, Gérard Lledo, M. Flesch, Isabel Chirivella, José Cortiñas Abrahantes
Publikováno v:
Journal of Clinical Oncology. 25:3224-3229
Purpose In the OPTIMOX1 trial, previously untreated patients with advanced colorectal cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and oxaliplatin that were administered until progression in the control arm or
Autor:
N. Perez-Staub, Aimery de Gramont, Annette K. Larsen, Pascal Artru, Benoist Chibaudel, Christophe Louvet, F. Maindrault-Goebel, Christophe Tournigand, Gérard Lledo
Publikováno v:
Current Colorectal Cancer Reports. 3:123-126
Generally patients with advanced colorectal cancer have several lines of chemotherapy with prolonged survival, and some benefit from surgery for initially unresectable metastasis. This provides strong rationale to study the best strategy to optimize
Autor:
Benoist Chibaudel, Franck Bonnetain, N. Perez-Staub, Aimery de Gramont, Marie-Line Garcia-Larnicol, Thomas Filleron, Momar Diouf, Christophe Louvet, Christophe Tournigand, Alexandra Hadengue, Marine Hug de Larauze, Sarah Dumont
Publikováno v:
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, BioMed Central, 2014, 12, pp.69. ⟨10.1186/1477-7525-12-69⟩
Health and Quality of Life Outcomes, 2014, 12, pp.69. ⟨10.1186/1477-7525-12-69⟩
Health and Quality of Life Outcomes, BioMed Central, 2014, 12, pp.69. ⟨10.1186/1477-7525-12-69⟩
Health and Quality of Life Outcomes, 2014, 12, pp.69. ⟨10.1186/1477-7525-12-69⟩
International audience; Background: Health-related quality of life (QoL) has prognostic value in many cancers. A recent study found that the performance of prognostic systems for metastatic colorectal cancer (mCRC) were improvable. We evaluated the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceef5b4462d00b221463a72cc892cd53
https://hal.sorbonne-universite.fr/hal-01327781
https://hal.sorbonne-universite.fr/hal-01327781
Autor:
Christophe Louvet, Andrés Cervantes, A. de Gramont, Elisabeth Carola, Marc Buyse, Fernando Rivera, Christophe Tournigand, Benoist Chibaudel, N. Perez-Staub, Thierry André, Arie Figer, Gérard Lledo, M. Flesch, Pascal Artru, Laurent Mineur
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 20(8)
Background Alkaline phosphatase (ALP) is a strong prognostic factor in patients with metastatic colorectal cancer (MCRC). Patients with ALP more than three times the upper limit of normal (ULN) were excluded from our previous studies evaluating chemo
Autor:
Christophe Tournigand, Aimery de Gramont, Christophe Louvet, Elisabeth Carola, Thierry André, Philippe Colin, Andre Cervantes, Ramón Barceló, N. Perez-Staub, M. Flesch, Gérard Lledo, Arie Figer
Publikováno v:
Cancer. 110(12)
BACKGROUND. Patients older than 75 years of age are usually excluded from metastatic colorectal cancer randomized studies. The OPTIMOX1 study evaluated FOLFOX7, a simplified (s) leucovorin (LV) and 5-fluorouracil (5FU) regimen (sLV5FU2) with high-dos
Autor:
Aimery de Gramont, Isabelle Tabah-Fisch, Arie Figer, Isabel Chirivella, Christophe Louvet, Marc Buyse, Gérard Lledo, Laurent Mineur, Pierre-Luc Etienne, Thierry André, Fernando Rivera, Christophe Tournigand, M. Flesch, N. Perez-Staub, Andrés Cervantes, Elisabeth Carola
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(3)
Purpose In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative neurotoxicity of oxaliplatin often requires therapy to be stopped in patients
Autor:
Nora Zeghib, N. Perez-Staub, F. Maindrault-Goebel, Christophe Louvet, Thierry André, Christophe Tournigand, Aimery de Gramont
Publikováno v:
European journal of cancer (Oxford, England : 1990). 41(15)
Oxaliplatin is a platinum salt that is particularly effective in treating gastrointestinal tumours. Its increased use has resulted in emergence of allergic reactions, including anaphylactic shock. Allergic reactions to oxaliplatin documented over the